Breaking News

Intranasal Inhibitor Blocks Omicron and Other SARS-CoV-2 Variants

January 15, 2022 • 5:00 pm CST
(Precision Vaccinations News)

A molecule developed by researchers at the University of Helsinki can inactivate the SARS-CoV-2 coronavirus spike protein and may offer short-term protection against the virus.

Announced by the University of Helsinki on January 10, 2022, cell cultures and animal studies show that TriSb92, a new molecule developed by the researchers, protects against coronavirus infection for at least eight hours, even in cases of high exposure risk.

The TriSb92 molecule is based on an entirely new technical solution. In contrast to vaccine protection, the effect of TriSb92 begins immediately after its administration.

“In animal models, nasally administered TriSb92 offered protection against infection in an exposure situation where all unprotected mice were infected,” says Postdoctoral Researcher Anna Mäkelä, the first author of the study, in a press statement.

The product, which is nasally administered, could serve as a kind of biological protection against coronavirus infection sprayed on the mucous membranes.

“In other words, we can fairly confidently assume that future SARS-CoV-2 variants and perhaps even entirely new coronaviruses may threaten to cause pandemics are susceptible to TriSb92,” Mäkelä added.

The findings have been published in an as of yet non-refereed report published on December 28, 2021.

Our Trust Standards: Medical Advisory Committee

Share